Daxor (DXR) vs Harvard Bioscience (HBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harvard Bioscience (HBIO) has outperformed Daxor (DXR) over the past year, gaining 84.8% versus a loss of 20.0%. Over five years, DXR leads with a -7.0% price change compared with -88.1% for HBIO. Daxor is the larger company by market cap ($61.2 million vs $37.3 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXR | HBIO |
|---|---|---|
| Share price | $10.49 | $8.20 |
| Market cap | $61.21M | $37.33M |
| 1-day change | +0.24% | +0.86% |
| YTD return | -29.08% | +21.34% |
| 1-year return | -20.03% | +84.77% |
| 5-year return | -7.02% | -88.11% |
| P/E ratio (TTM) | 9.53 | — |
| Forward P/E | — | 12.71 |
| EPS (TTM) | $1.10 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.76 | $9.40 |
| 52-week low | $8.56 | $3.80 |
| Distance from 52-week high | -28.96% | -12.77% |
| Analyst consensus | none | none |
| Avg. price target upside | +90.75% | -8.54% |
| Average volume | 17.27K | 17.98K |
| Shares outstanding | 5.84M | 4.55M |
| Employees | — | 316 |
| Sector | Health Care | Industrials |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HBIO has outperformed DXR by 104.8 percentage points over the past year.
- The two companies sit in different sectors: Daxor in Health Care and Harvard Bioscience in Industrials.
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Health Care · Medical/Dental Instruments
About Harvard Bioscience
HBIO stock →Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees
DXR vs HBIO FAQ
Which is bigger, Daxor or Harvard Bioscience?
Daxor (DXR) is larger, with a market capitalization of $61.21M compared with $37.33M for Harvard Bioscience (HBIO).
Which stock has performed better over the past year, DXR or HBIO?
HBIO returned +84.77% over the past 12 months, compared with -20.03% for DXR (price return, excluding dividends). Past performance does not predict future results.
Are Daxor and Harvard Bioscience in the same industry?
No. Daxor is in the Health Care sector, while Harvard Bioscience is in Industrials.